Dr Francis Collins, Director of the National Institutes of Health (NIH), holds up a model of SARS-CoV-2, known as the novel coronavirus, during a U.S. Senate Appropriations Subcommittee Hearing on the plan to research, manufacture and distribute a coronavirus vaccine, known as Operation Warp Speed on Capitol Hill in Washington, D.C, U.S., July 2, 2020. Saul Loeb/Pool via REUTERS

The world’s largest vaccine-maker GSK has put its vaccine booster technology into a potential new COVID-19 shot, to be developed with a Canadian biopharmaceutical company backed by tobacco company Philip Morris.

Rather than developing its own vaccine in the global race to combat the pandemic, GSK has instead focused on contributing its adjuvant technology to at least seven other global companies, including Sanofi and China’s Clover.    

The latest deal, with Canadian firm Medicago, uses plant-based technology that differs from GSK’s other coronavirus-partnerships and boosts the London-listed company’s chances of finding a successful candidate and scaling production relatively quickly.

There are no approved vaccines for the respiratory illness caused by the new coronavirus, but 19 vaccines are being trialed in humans globally, and some treatments, such as Gilead’s Remdesivir, have been approved in certain regions.

General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs
General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs

Medicago’s approach, already used in a flu vaccine awaiting Canadian approval, takes the leaves of a plant as bioreactors to produce one of the three spike proteins of the novel coronavirus, the S-spike, which can be then used in the vaccine with GSK’s adjuvant.

GSK said the companies aimed to make their vaccine available in the first half of next year and produce about 100 million doses by the end of 2021. An early-stage human trial of three different dosage levels is expected to begin in mid-July. 

Adjuvants, or efficacy boosters, are added to some vaccines to increase the immune response to achieve more lasting immunity against infection.

Medicago, headquartered in Quebec City, Canada, is privately owned. PMI has a 33% stake, and Mitsubishi Tanabe Pharma holds the remainder.

PMI has said it is evaluating options for its stake in Medicago. It was not immediately available for further comment.

—Reuters


Global Heroes Magazine

Subscribe to our Newsletter and Access all issues of Global Heroes Magazine straight in your inbox. All free, no purchase necessary. Uplifting stories, highlighting the inspirational efforts of everyday people, celebrities and organizations, who are diligently working together towards practical solutions to global problems.